* Company proceeded with IPO due to investor support -CFO (Adds context, company background): HONG KONG (Reuters) - Innovent Biologics Inc has priced its Hong Kong initial public offering (IPO) near the top of its marketing range to raise $421 million, two people familiar with the matter said, indicating renewed enthusiasm in a sector blighted by falling stocks.